ASCO26 highlights: Ivonescimab’s OS win, the RAS revolution, and more from Lilly, Pfizer, J&J – FirstWord Pharma
- ASCO26 highlights: Ivonescimab’s OS win, the RAS revolution, and more from Lilly, Pfizer, J&J FirstWord Pharma
- BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA statnews.com
- Misty Dawn Shields: Fabulous “Research to Practice” session on updates in Small Cell Lung Cancer Oncodaily
- ASCO 2026: key readouts in lung cancer Clinical Trials Arena
- ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer BioPharma Dive
المصدر: Google News — UK / BUSINESS
0
مشاهدة





